NasdaqGS - Delayed Quote • USD
BioMarin Pharmaceutical Inc. (BMRN)
At close: May 10 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 17 | 17 | 18 | 18 |
Avg. Estimate | 0.35 | 0.48 | 1.85 | 2.78 |
Low Estimate | 0.17 | 0.27 | 1.29 | 1.36 |
High Estimate | 0.55 | 0.76 | 2.88 | 4.04 |
Year Ago EPS | 0.29 | 0.21 | 0.87 | 1.85 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 21 | 21 | 24 | 23 |
Avg. Estimate | 660.16M | 691.6M | 2.74B | 3.1B |
Low Estimate | 651.8M | 672.54M | 2.7B | 2.82B |
High Estimate | 681.54M | 728.22M | 2.84B | 3.32B |
Year Ago Sales | -- | 608.68M | 2.42B | 2.74B |
Sales Growth (year/est) | -- | 13.60% | 13.40% | 13.00% |
Earnings History
CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
---|---|---|---|---|
EPS Est. | 0.23 | 0.23 | 0.23 | 0.34 |
EPS Actual | 0.29 | 0.21 | 0.11 | 0.46 |
Difference | 0.06 | -0.02 | -0.12 | 0.12 |
Surprise % | 26.10% | -8.70% | -52.20% | 35.30% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.35 | 0.48 | 1.85 | 2.78 |
7 Days Ago | 0.35 | 0.48 | 1.85 | 2.78 |
30 Days Ago | 0.39 | 0.45 | 1.72 | 2.78 |
60 Days Ago | 0.37 | 0.43 | 1.65 | 2.79 |
90 Days Ago | 0.42 | 0.45 | 1.95 | 3.22 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | 8 | 15 | 20 | 11 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
CURRENCY IN USD | BMRN | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 20.70% | -- | -- | 8.40% |
Next Qtr. | 128.60% | -- | -- | 11.90% |
Current Year | 112.60% | -- | -- | 5.60% |
Next Year | 50.30% | -- | -- | 13.00% |
Next 5 Years (per annum) | 43.00% | -- | -- | 11.05% |
Past 5 Years (per annum) | -0.19% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Morgan Stanley: Overweight to Overweight | 4/26/2024 |
Maintains | Canaccord Genuity: Hold to Hold | 4/26/2024 |
Maintains | Citigroup: Neutral to Neutral | 4/25/2024 |
Maintains | Scotiabank: Sector Perform to Sector Perform | 4/25/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/25/2024 |
Maintains | Wells Fargo: Overweight to Overweight | 4/25/2024 |
Related Tickers
ALNY Alnylam Pharmaceuticals, Inc.
150.47
-0.59%
INCY Incyte Corporation
53.06
-0.82%
ARGX argenx SE
374.63
-2.07%
IONS Ionis Pharmaceuticals, Inc.
39.08
-0.99%
SRPT Sarepta Therapeutics, Inc.
131.82
-0.36%
BBIO BridgeBio Pharma, Inc.
29.10
+1.29%
HALO Halozyme Therapeutics, Inc.
43.15
-1.57%
IMVT Immunovant, Inc.
29.39
-1.04%
BPMC Blueprint Medicines Corporation
106.70
-1.51%
AGIO Agios Pharmaceuticals, Inc.
33.00
+0.24%